^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    sturlimogene erparepvec (RP2)

    i
    Other names: RP2
    Associations

    News

    Trials
    Company:
    Replimune
    Drug class:
    CTLA4 inhibitor, G-CSF stimulant
    Related drugs:
    Associations

    News

    Trials
    7d
    RP2-001-18: Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=36, Active, not recruiting, Replimune Inc. | Trial completion date: Apr 2028 --> Oct 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • First-in-human
    |
    Opdivo (nivolumab) • sturlimogene erparepvec (RP2)
    17d
    RPL-123-01: A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 (2025-521621-33-00)
    P4, N=41, Not yet recruiting, Replimune Group Inc.
    New P4 trial
    |
    RP3 • Tudriqev (vusolimogene oderparepvec-wtpg) • sturlimogene erparepvec (RP2)
    1m
    RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC (clinicaltrials.gov)
    P2, N=5, Terminated, Replimune Inc. | Trial completion date: Mar 2027 --> Aug 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2027 --> Aug 2025; Business reasons.
    Trial completion date • Trial termination • Trial primary completion date • Mismatch repair • pMMR
    |
    EGFR (Epidermal growth factor receptor)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • RP3 • sturlimogene erparepvec (RP2)
    2ms
    RPx: A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Replimune Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    RP3 • Tudriqev (vusolimogene oderparepvec-wtpg) • sturlimogene erparepvec (RP2)
    2ms
    Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, Abramson Cancer Center at Penn Medicine | Initiation date: Nov 2025 --> Apr 2026
    Trial initiation date
    |
    docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • sturlimogene erparepvec (RP2)
    5ms
    RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, City of Hope Medical Center
    New P2 trial
    |
    Fotivda (tivozanib) • sturlimogene erparepvec (RP2)
    6ms
    Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC (clinicaltrials.gov)
    P2, N=60, Recruiting, Replimune Inc. | N=30 --> 60
    Enrollment change
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • sturlimogene erparepvec (RP2)
    7ms
    RPx: A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, Replimune Inc. | Initiation date: Jun 2025 --> Nov 2025
    Trial initiation date
    |
    RP3 • Tudriqev (vusolimogene oderparepvec-wtpg) • sturlimogene erparepvec (RP2)
    8ms
    Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, Abramson Cancer Center at Penn Medicine
    New P2 trial
    |
    docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • sturlimogene erparepvec (RP2)
    12ms
    RPx: A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, Replimune Inc.
    New trial
    |
    RP3 • Tudriqev (vusolimogene oderparepvec-wtpg) • sturlimogene erparepvec (RP2)
    over1year
    RP2-202: A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma (clinicaltrials.gov)
    P2/3, N=280, Recruiting, Replimune Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • sturlimogene erparepvec (RP2)
    over1year
    Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC (clinicaltrials.gov)
    P2, N=30, Recruiting, Replimune Inc. | Not yet recruiting --> Recruiting | N=60 --> 30 | Trial completion date: Jul 2027 --> Jul 2028 | Trial primary completion date: Apr 2027 --> Dec 2027
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Oncolytic virus • Metastases
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • sturlimogene erparepvec (RP2)